Psilocybin depression study cut short: did the benefits last?
NCT ID NCT04353921
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 26 people with major depressive disorder for one year after they received a single dose of psilocybin or a niacin control. Researchers used web surveys and phone interviews to track depression symptoms over time. The study was terminated early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Innovative Clinical Research, Inc. (formerly Segal Trials)
Lauderhill, Florida, 33319, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a structured care pathway ease teen depression?
- Can a nasal spray break through tough depression?
- Could a new drug offer hope for Treatment-Resistant depression?
- Targeting depression: can MRI-Guided brain zaps rewire key circuits?
- Can a psychedelic trip plus a gentle ear zap lift depression?
- Can a smart brain implant outsmart depression?